Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 3/23/2026 | $325.00 → $320.00 | Buy | BofA Securities | |
| 3/20/2026 | $135.00 | Buy → Hold | DZ Bank | |
| 3/16/2026 | $12.00 | Neutral → Overweight | Analyst | |
| 3/5/2026 | $267.00 → $268.00 | Neutral | Rosenblatt | |
| 3/4/2026 | $116.00 | Underperform → Mkt Perform | Bernstein | |
| 3/4/2026 | $110.00 → $145.00 | Market Perform → Outperform | Telsey Advisory Group | |
| 3/3/2026 | $239.00 → $248.00 | Underweight | Barclays | |
| 2/27/2026 | $103.00 | Underperform | BofA Securities |
AUSTIN, Texas, April 07, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: As regulatory expectations intensify and manufacturing complexity grows, pharmaceutical companies are moving beyond traditional quality systems toward a new paradigm: embedding artificial intelligence (AI) directly into operations as a real-time compliance layer. Rather than relying on retrospective audits and manual oversight, AI-driven systems now continuously monitor, validate and optimize production processes to align with evolving Good Manufacturing Practice (GMP) standards. This structural shift is increasingly visible across the industry and aligns with companies such as Oncotelic Therapeutics Inc. (OTC
Nvidia's top 1% AI engineer leaves world's most valuable company to lead self-storage's first Chief AI Officer role at 10 FederalRALEIGH, N.C., April 6, 2026 /PRNewswire/ -- 10 Federal, a leading technology-driven self-storage owner and operator, today announced the appointment of Christopher Taylor as its Chief A.I. Officer (CAIO), a newly created executive position that represents the first dedicated C-suite AI role in the self-storage industry. Taylor joins 10 Federal from Nvidia (NASDAQ:NVDA), the global leader in AI computing, where he served as a Senior Software Engineer working across both the data center division and the autonomous vehicle platform, and ranked among the top 1% of AI
WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi m
BofA Securities reiterated coverage of Apple with a rating of Buy and set a new price target of $320.00 from $325.00 previously
DZ Bank downgraded Alibaba from Buy to Hold and set a new price target of $135.00
Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00
4 - Apple Inc. (0000320193) (Issuer)
4 - Apple Inc. (0000320193) (Issuer)
For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a
For Immediate Release: September 12, 2024 Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user’s hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hea
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
6-K - Alibaba Group Holding Ltd (0001577552) (Filer)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
424B5 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
Nvidia's top 1% AI engineer leaves world's most valuable company to lead self-storage's first Chief AI Officer role at 10 FederalRALEIGH, N.C., April 6, 2026 /PRNewswire/ -- 10 Federal, a leading technology-driven self-storage owner and operator, today announced the appointment of Christopher Taylor as its Chief A.I. Officer (CAIO), a newly created executive position that represents the first dedicated C-suite AI role in the self-storage industry. Taylor joins 10 Federal from Nvidia (NASDAQ:NVDA), the global leader in AI computing, where he served as a Senior Software Engineer working across both the data center division and the autonomous vehicle platform, and ranked among the top 1% of AI
WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Rajani Dinavahi, MD, as Chief Medical Officer (CMO). Dr. Dinavahi brings more than two decades of experience in healthcare and biotechnology, spanning multiple therapeutic areas and modalities. She has extensive experience across immuno-oncology, autoimmune diseases, metabolic disease, nephrology and transplantation, with a track record of advancing programs from early development through Phase 3 and regulatory approval. Dr. Dinavahi m
MINNEAPOLIS, March 11, 2026 /PRNewswire/ -- Target Corporation (NYSE:TGT) is lowering prices on more than 3,000 on-trend items across its apparel and home assortment, baby essentials and select food and beverages as guests get ready for spring.The price reductions* – most of which are 5% to 20% lower than the original price – are the latest example of Target's strategy to deliver style and design at an incredible value to guests and drive long-term, sustainable growth for the company."Busy families are thinking about value as they begin to update their homes and wardrobes for spring," said Cara Sylvester, executive vice president and chief merchandising officer, Target. "We're delivering by
MONTEVIDEO, Uruguay, March 31, 2026 (GLOBE NEWSWIRE) -- DLocal Limited (NASDAQ:DLO, "dLocal" or the "Company")), a leading financial technology company powering payments across emerging markets, intends to release financial results for its first fiscal quarter ended March 31, 2026 on May 14, 2026 after market close. The Company will host a conference call and video webcast on May 14, 2026 at 6:00 p.m. Eastern Time. Please click here to pre-register for the conference call and obtain your dial in number and passcode. The live conference call can be also accessed via audio webcast at the investor relations section of the Company's website, at https://investor.dlocal.com/. An archive of the
Alibaba Group Holding Limited (NYSE: BABA and HKEX: 9988 (HKD Counter) and 89988 (RMB Counter), "Alibaba" or "Alibaba Group") today announced its financial results for the quarter ended December 31, 2025. "This quarter, Alibaba maintained strong investments across our core pillars of AI and consumption. AI is and will continue to be one of our primary growth engines. Our Cloud Intelligence Group's revenue is up 36% with AI-related product revenue delivering triple-digit growth for the tenth consecutive quarter. Our Model-as-a-Service (MaaS) platform is showing strong growth, emerging as a new engine driving cloud business growth. On the consumer side, we have integrated use cases across o
4Q25: Ending the year with strong growth momentum, with broad-based acceleration across key metrics. TPV at an all-time quarterly high of US$13.1 billion, growing 70% year-over-year, the fifth straight quarter above 50% year-over-year. Revenue up +65% year-over-year reaching US$338 million for the quarter. Gross profit reached US$116 million, up +38% year-over-year. Adjusted EBITDA up +38% year-over-year, representing 68% of gross profit, underscoring best-in-class operating leverage and disciplined cost management. Net income growth at +87% year-over-year. Solid free cash generation, with adjusted free cash flow to net income ratio at 117%. 2025: Demonstrated the scale of the emerging ma
SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)